NASDAQ:CYCC
Delisted

Cyclacel Pharmaceuticals Stock Signals

etoro logo Buy CYCC
*Your capital is at risk
$6.37
+0 (+0%)
At Close: Dec 10, 2025

Latest Data & Signals Issued

Below are some of the latest signals issued for Cyclacel Pharmaceuticals

General

Signal Type Signal Value Data
Score 0.000 62 days ( 0 %
Last Price $6.37 0 %
Performance History
7 Days
$6.37 $6.37
0%
30 Days
$6.37 $6.37
0%
12 Mos
$0.384 $6.37
1,557.55%

5/18

Active Buy Signals

Specific Signals

Short Term
Net score: 20.95
Signal Type Signal Value Importance Data
High / Low N/A Very Low $6.37 - $6.37
Trend - 3 mos 0 % High Width: 0 %
Pred. range - 3 mos N/A - N/A Low -100.00 % - -100.00 %
Volume Direction Sell High Volume: 1 · Direction: 0
Pivot Short Buy Very Low Dec 09, 2025 - 2 days
RSI Short Pivot Signal Buy Very Low Sep 19, 2025 - 58 days
Short MA 3 mos Sell Low Nov 30, -0001 - N/A days
Long MA 3 mos Sell Medium Nov 30, -0001 - N/A days
Short/Long MA 3 mos Sell Medium Nov 30, -0001 - N/A days

Unlock Short Term Signals

Get access to powerful short-term trading signals and real-time market insights

Subscribe Now
Long Term
Net score: 37.01
Signal Type Signal Value Importance Data
Trend - 12 mos 84.70 % Very High Width: 882.76 %
Pred. range - 12 mos $3.92 - $38.57 High -38.35 % - 505.90 %
Short MA 12 mos Sell Very High Aug 04, 2025 - 91 days
Long MA 12 mos Sell Very High Oct 28, 2025 - 31 days
Short/Long MA 12 mos Sell Very High Oct 28, 2025 - 31 days
Pivot Long Buy Low Sep 11, 2025 - 64 days
RSI Long Pivot Signal Buy Low Sep 30, 2025 - 51 days
Bollinger Sell Medium Nov 30, -0001 - N/A days
MACD Neutral High No Dates Stored For This Signal
Click to get the best stock tips daily for free!
ABOUT CYCLACEL PHARMACEUTICALS
Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-...
GOLDEN STAR
Ticker Change Signal Date
EAT
$140.46
13.43% Jun 05
TPR
$140.47
4.95% Jun 04
LITE
$905.00
1.83% Jun 01
RUN
$12.83
0.468% May 06
GLBE
$31.61
3.54% May 05

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE